nbkj
I, Robert Burns and Raghuram Selvaraju, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my
personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be
directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself
nor any members of my household is an officer, director or advisory board member of these companies.
A research analyst of the firm and/or the research analyst’s household has a financial interest in and own the securities of
BioNTech SE (including, without limitation, any option, right, warrant, future, long or short position).
As of December 31, 2021 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities
of BioNTech SE.
Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time
of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any
specific investment banking services or transaction but is compensated based on factors including total revenue and profitability
of the Firm, a substantial portion of which is derived from investment banking services.
The Firm or its affiliates did not receive compensation from BioNTech SE for investment banking services within twelve months
before, but will seek compensation from the companies mentioned in this report for investment banking services within three
months following publication of the research report.
The Firm does not make a market in BioNTech SE as of the date of this research report.
